{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:00:57Z","timestamp":1783771257908,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"crossref","award":["PYZ2017113"],"award-info":[{"award-number":["PYZ2017113"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"crossref","award":["16JL13"],"award-info":[{"award-number":["16JL13"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"crossref","award":["17JL(TTZX)03"],"award-info":[{"award-number":["17JL(TTZX)03"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"crossref","award":["ZYLX201808"],"award-info":[{"award-number":["ZYLX201808"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jpba.2018.06.011","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T11:39:49Z","timestamp":1528717189000},"page":"300-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Simultaneous determination of plasma methotrexate and 7-hydroxy methotrexate by UHPLC\u2013MS\/MS in patients receiving high-dose methotrexate therapy"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-4315","authenticated-orcid":false,"given":"Shenghui","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2018.06.011_bib0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","article-title":"PharmGKB summary: methotrexate pathway","volume":"21","author":"Mikkelsen","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.jpba.2018.06.011_bib0010","unstructured":"Hospira, Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/011719s117lbl.pdf, 2011."},{"key":"10.1016\/j.jpba.2018.06.011_bib0015","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2008-07-172106","article-title":"Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia","volume":"113","author":"French","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2018.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199610033351408","article-title":"Intrinsic and acquired resistance to methotrexate in acute leukemia","volume":"335","author":"Gorlick","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2018.06.011_bib0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1211\/0022357991772619","article-title":"Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man","volume":"51","author":"Jordan","year":"1999","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jpba.2018.06.011_bib0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchromb.2015.08.025","article-title":"Development and validation of a turbulent flow chromatography and tandem mass spectrometry method for the quantitation of methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum","volume":"1002","author":"Schofield","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.06.011_bib0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1172\/JCI108308","article-title":"7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate","volume":"57","author":"Jacobs","year":"1976","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jpba.2018.06.011_bib0040","first-page":"599","article-title":"The influence of 7-OH methotrexate metabolite on clinical relevance of methotrexate determination","volume":"57","author":"Klapkova","year":"2011","journal-title":"Clin. Lab."},{"key":"10.1016\/j.jpba.2018.06.011_bib0045","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2011-03-321349","article-title":"How I treat primary CNS lymphoma","volume":"118","author":"Ferreri","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jpba.2018.06.011_bib0050","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.xphs.2018.01.004","article-title":"Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma","volume":"107","author":"Mei","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2018.06.011_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-4939-3252-8_23","article-title":"Development of an assay for methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum by LC-MS\/MS","volume":"1383","author":"Schofield","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jpba.2018.06.011_bib0060","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/10826076.2016.1243558","article-title":"Determination of methotrexate, 7-hydroxymethotrexate, and 2,4-diamino-N(10)-methylpteroic acid by LC\u2013MS\/MS in plasma and cerebrospinal fluid and application in a pharmacokinetic analysis of high-dose methotrexate","volume":"39","author":"Roberts","year":"2016","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2018.06.011_bib0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jchromb.2016.10.035","article-title":"Development and validation of LC\u2013MS\/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: correlation with genetic polymorphism","volume":"1038","author":"Al-Ghobashy","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.06.011_bib0070","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/bmc.3408","article-title":"A simple, rapid and reliable liquid chromatography-mass spectrometry method for determination of methotrexate in human plasma and its application to therapeutic drug monitoring","volume":"29","author":"Wu","year":"2015","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2018.06.011_bib0075","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.4155\/bio.13.73","article-title":"The advantages of microflow LC\u2013MS\/MS compared with conventional HPLC\u2013MS\/MS for the analysis of methotrexate from human plasma","volume":"5","author":"Christianson","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2018.06.011_bib0080","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1039\/C3AY40815A","article-title":"A fast LC\u2013MS\/MS assay for methotrexate monitoring in plasma: validation, comparison to FPIA and application in the setting of carboxypeptidase therapy","volume":"6","author":"Bouqui\u00e9","year":"2013","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jpba.2018.06.011_bib0085","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/FTD.0b013e31825bb368","article-title":"A U-HPLC-ESI-MS\/MS-based stable isotope dilution method for the detection and quantitation of methotrexate in plasma","volume":"34","author":"den Boer","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2018.06.011_bib0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/bmc.1628","article-title":"Simple and sensitive HPLC method for the fluorometric determination of methotrexate and its major metabolites in human plasma by post-column photochemical reaction","volume":"26","author":"Uchiyama","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2018.06.011_bib0095","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"FDA","year":"2013"},{"key":"10.1016\/j.jpba.2018.06.011_bib0100","series-title":"Committee for Medicinal Products for Human Use, Guideline on Bioanalytical Method Validation. EMEA\/ CHMP\/ EWP\/192217\/2009 Rev. 1 Corr. 2** (21July2011)","author":"EMEA","year":"2011"},{"key":"10.1016\/j.jpba.2018.06.011_bib0105","series-title":"Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guideline","author":"CLSI","year":"2007"},{"key":"10.1016\/j.jpba.2018.06.011_bib0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jchromb.2017.11.024","article-title":"Development, validation, and application of an UPLC-MS\/MS method for norvancomycin analysis in human blood plasma","volume":"1072","author":"Mei","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.06.011_bib0115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000000476","article-title":"Elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment","volume":"68","author":"Post","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jpba.2018.06.011_bib0120","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2116\/analsci.33.665","article-title":"UPLC-MS\/MS analysis of methotrexate in human plasma and comparison with the fluorescence polarization immunoassay","volume":"33","author":"Mei","year":"2017","journal-title":"Anal. Sci."},{"key":"10.1016\/j.jpba.2018.06.011_bib0125","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-60761-459-3_34","article-title":"Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for monitoring methotrexate in the setting of carboxypeptidase-G2 therapy","volume":"603","author":"Kumar","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jpba.2018.06.011_bib0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-017-2435-7","article-title":"Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study","volume":"133","author":"Houillier","year":"2017","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.jpba.2018.06.011_bib0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/0366-6999.147829","article-title":"Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution","volume":"128","author":"Zhang","year":"2015","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.jpba.2018.06.011_bib0140","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bcp.2015.05.010","article-title":"Interspecies differences in the metabolism of methotrexate: an insight into the active site differences between human and rabbit aldehyde oxidase","volume":"96","author":"Choughule","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2018.06.011_bib0145","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/0091270010381496","article-title":"Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis","volume":"51","author":"Baluom","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2018.06.011_bib0150","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10428190701824569","article-title":"Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells","volume":"49","author":"Fotoohi","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jpba.2018.06.011_bib0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","article-title":"Molecular basis of antifolate resistance","volume":"26","author":"Assaraf","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jpba.2018.06.011_bib0160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1248\/yakushi.129.1001","article-title":"Erythrocyte methotrexate-polyglutamate assay using fluorescence polarization immunoassay technique: application to the monitoring of patients with rheumatoid arthritis","volume":"129","author":"Inoue","year":"2009","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.jpba.2018.06.011_bib0165","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJMc1507547","article-title":"Acute methotrexate-induced crystal nephropathy","volume":"373","author":"Garneau","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2018.06.011_bib0170","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jpba.2018.06.011_bib0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2125.2011.04054.x","article-title":"High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients","volume":"73","author":"Holmboe","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2018.06.011_bib0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-016-3043-5","article-title":"Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses","volume":"78","author":"Campbell","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2018.06.011_bib0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s13318-016-0338-1","article-title":"Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies: utilization of routine clinical monitoring parameters","volume":"42","author":"Nader","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jpba.2018.06.011_bib0190","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.clinthera.2012.06.022","article-title":"ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis","volume":"34","author":"Kim","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2018.06.011_bib0195","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4236\/pp.2013.42020","article-title":"Population pharmacokinetics of methotrexate in Egyptian children with lymphoblastic leukemia","volume":"4","author":"EL Desoky","year":"2013","journal-title":"Pharmacol. Pharm."},{"key":"10.1016\/j.jpba.2018.06.011_bib0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FTD.0b013e3181945624","article-title":"Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma","volume":"31","author":"Colom","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2018.06.011_bib0205","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/CAD.0b013e3282f21376","article-title":"High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy","volume":"19","author":"Dupuis","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jpba.2018.06.011_bib0210","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/jcpt.12060","article-title":"Methotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination","volume":"38","author":"Al-Quteimat","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2018.06.011_bib0215","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2011-0431","article-title":"Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors","volume":"17","author":"Bezabeh","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.jpba.2018.06.011_bib0220","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/1060028016661572","article-title":"Methotrexate elimination when coadministered with levetiracetam","volume":"50","author":"Reeves","year":"2016","journal-title":"Ann. Pharmacother."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518307817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518307817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T11:04:55Z","timestamp":1563966295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518307817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":44,"alternative-id":["S0731708518307817"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2018.06.011","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of plasma methotrexate and 7-hydroxy methotrexate by UHPLC\u2013MS\/MS in patients receiving high-dose methotrexate therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2018.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}